 Behind the success of the Brazilian anti-aids program, the indian industrial performance in pharmaceuticalsDerrière le succès du programme antisida brésilien, les performances industrielles indiennes en pharmacieSamira Guennif (samira@guennif.com)
Post-Print from HAL Abstract: The Brazilian free and universal access program to anti-AIDS drugs has been described as a model whose replication in the developing world is largely discussed. According to the literature, this success of this program is related to the Brazilian capacity to bargain price reductions with patent holders, built on a constant threat to resort to compulsory license and the very existence of national capabilities in the pharmaceutical production. This paper shows that the successful scaling-up of the Brazilian anti-AIDS program owes a lot to the success of India in the pharmaceutical sector. Indeed, the Brazilian threat to resort to compulsory license has more to do with the tough competition exerted by Indian firms endowed with large industrial capabilities on the antiretroviral market than the limited industrial performances of Brazilian firms. Thus, the replication of this model in developing countries is questioned, especially for those deprived of industrial capabilities in pharmaceuticals. Keywords: Brésil; Inde; VIH/Sida; médicament; brevet.; Brazil; India; HIV/AIDS; medicine; patent. (search for similar items in EconPapers) Published in Journal de gestion et d’économie médicales, 2012, 30 (2), pp.111-122 There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it. Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01345867 Access Statistics for this paper More papers in Post-Print from HAL |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to econpapers@oru.se.
EconPapers is hosted by the
School of Business at Örebro University.